Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.
|Articles|June 25, 2019
FDA Approves Generic Oseltamivir Phosphate Capsules
Author(s)Contagion® Editorial Staff
According to a press release issued by the manufacturer, the products are the therapeutic equivalent to Genentech’s Tamiflu capsules.
Advertisement
The US Food and Drug Administration has
According to a press release issued by Alembic, the products are the therapeutic equivalent to Genentech’s Tamiflu capsules.
The capsules are indicated for treating uncomplicated, acute illness due to influenza A and B infection. The capsules are approved for use in patients 2 weeks of age and older, who have been experiencing symptoms of influenza for less than 48 hours. The indication also includes prophylaxis of influenza A and B in patients 1 year and older.
According to the press release, oseltamivir phosphate capsules had an estimated market size of $647 million for 12 months ending in December of 2018 according to IQIVA.
Advertisement
Related to this article
The CHMP adopted a positive opinion on an extension of indication for AstraZeneca's H5N1 pandemic influenza vaccine at its October meeting.
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
An APP-driven complex outpatient antimicrobial therapy (COpAT) program for patients with bone and joint infections cut mean time to post-discharge follow-up from 20.1 to 9.7 days but did not significantly reduce 30-day readmissions or emergency department visits.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with Staphylococcus aureus Bacteremia (SAB). This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline.
Labcorp data presented at IDWeek 2026 show measles PCR testing nearly quadrupled and positivity rose sharply from April 2025 through March 2026, as clinicians shift toward guideline-recommended molecular testing amid ongoing US outbreaks.
Advertisement
Advertisement
Trending on Contagion Live
1
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
2
A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia
3
Measles Update: October 30, 2026
4
AI-Designed Phage Treatment of Resistant Bacterial Infection
5